Catalent’s (CTLT) Sector Perform Rating Reiterated at Royal Bank of Canada

Catalent (NYSE:CTLTGet Free Report)‘s stock had its “sector perform” rating reaffirmed by analysts at Royal Bank of Canada in a report issued on Tuesday, Benzinga reports. They presently have a $63.50 target price on the stock, up from their previous target price of $58.00. Royal Bank of Canada’s price target points to a potential upside of 12.39% from the company’s previous close.

Other analysts have also recently issued reports about the company. Wells Fargo & Company cut their target price on Catalent from $50.00 to $42.00 and set an “equal weight” rating on the stock in a research note on Thursday, November 16th. StockNews.com raised Catalent to a “sell” rating in a research note on Thursday, January 25th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, November 14th. Barclays lifted their price objective on Catalent from $45.00 to $47.00 and gave the company an “equal weight” rating in a research report on Thursday, January 25th. Finally, Robert W. Baird raised Catalent from a “neutral” rating to an “outperform” rating and lifted their price objective for the company from $45.00 to $53.00 in a research report on Thursday, November 16th. Two analysts have rated the stock with a sell rating, nine have issued a hold rating and three have issued a buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $52.46.

Check Out Our Latest Analysis on CTLT

Catalent Stock Down 3.4 %

CTLT opened at $56.50 on Tuesday. The company has a market cap of $10.21 billion, a P/E ratio of -10.78, a P/E/G ratio of 3.69 and a beta of 1.20. The business’s 50-day moving average price is $46.31 and its 200-day moving average price is $44.68. The company has a current ratio of 1.70, a quick ratio of 1.19 and a debt-to-equity ratio of 1.13. Catalent has a 12 month low of $31.45 and a 12 month high of $74.49.

Catalent (NYSE:CTLTGet Free Report) last posted its earnings results on Wednesday, November 15th. The company reported ($0.10) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.04. The company had revenue of $982.00 million for the quarter, compared to analysts’ expectations of $939.62 million. Catalent had a positive return on equity of 1.55% and a negative net margin of 22.36%. Catalent’s quarterly revenue was down 3.9% on a year-over-year basis. During the same period last year, the firm earned $0.25 earnings per share. On average, equities analysts expect that Catalent will post 0.52 EPS for the current year.

Hedge Funds Weigh In On Catalent

Several large investors have recently made changes to their positions in CTLT. Cetera Advisor Networks LLC lifted its holdings in shares of Catalent by 7.1% during the first quarter. Cetera Advisor Networks LLC now owns 1,953 shares of the company’s stock valued at $217,000 after purchasing an additional 130 shares during the last quarter. Private Advisor Group LLC lifted its holdings in shares of Catalent by 18.0% during the first quarter. Private Advisor Group LLC now owns 2,957 shares of the company’s stock valued at $328,000 after purchasing an additional 452 shares during the last quarter. Panagora Asset Management Inc. raised its holdings in Catalent by 125.8% in the 1st quarter. Panagora Asset Management Inc. now owns 12,979 shares of the company’s stock worth $1,439,000 after acquiring an additional 7,231 shares during the last quarter. Yousif Capital Management LLC raised its holdings in Catalent by 2.0% in the 1st quarter. Yousif Capital Management LLC now owns 24,561 shares of the company’s stock worth $2,724,000 after acquiring an additional 470 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in Catalent by 1.8% in the 1st quarter. Dimensional Fund Advisors LP now owns 991,019 shares of the company’s stock worth $109,904,000 after acquiring an additional 17,813 shares during the last quarter.

About Catalent

(Get Free Report)

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.

Further Reading

Analyst Recommendations for Catalent (NYSE:CTLT)

Receive News & Ratings for Catalent Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent and related companies with MarketBeat.com's FREE daily email newsletter.